Mark G. Kris, MD

Articles

Dr. Kris on Search for Biomarkers in Advanced Squamous NSCLC

November 13th 2019

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non­–small cell lung cancer.

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

October 23rd 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Dr. Kris on the RELAY Trial in EGFR+ NSCLC

August 30th 2019

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.

Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLC

June 13th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Kris on Personalizing Therapy in Lung Cancer

March 20th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses personalizing therapy in the treatment of patients with lung cancer.

Dr. Kris Discusses Role of Antiangiogenesis in Lung Cancer

January 25th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of antiangiogenesis in the treatment of patients with lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

November 10th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC

September 28th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

Dr. Kris on Combination Chemotherapy Approaches in NSCLC

April 18th 2018

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

x